Literature DB >> 22764578

Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs.

W Neuhaus1, J Mandikova, R Pawlowitsch, B Linz, B Bennani-Baiti, R Lauer, B Lachmann, C R Noe.   

Abstract

In the course of our validation program testing blood-brain barrier (BBB) in vitro models for their usability as tools in drug discovery it was evaluated whether an established Transwell model based on porcine cell line PBMEC/C1-2 was able to differentiate between the transport properties of first and second generation antihistaminic drugs. First generation antihistamines can permeate the BBB and act in the central nervous system (CNS), whereas entry to the CNS of second generation antihistamines is restricted by efflux pumps such as P-glycoprotein (P-gP) located in brain endothelial cells. P-gP functionality of PBMEC/C1-2 cells grown on Transwell filter inserts was proven by transport studies with P-gP substrate rhodamine 123 and P-gP blocker verapamil. Subsequent drug transport studies with the first generation antihistamines promethazine, diphenhydramine and pheniramine and the second generation antihistamines astemizole, ceterizine, fexofenadine and loratadine were accomplished in single substance as well as in group studies. Results were normalised to diazepam, an internal standard for the transcellular transport route. Moreover, effects after addition of P-gP inhibitor verapamil were investigated. First generation antihistamine pheniramine permeated as fastest followed by diphenhydramine, diazepam, promethazine and second generation antihistaminic drugs ceterizine, fexofenadine, astemizole and loratadine reflecting the BBB in vivo permeability ranking well. Verapamil increased the transport rates of all second generation antihistamines, which suggested involvement of P-gP during their permeation across the BBB model. The ranking after addition of verapamil was significantly changed, only fexofenadine and ceterizine penetrated slower than internal standard diazepam in the presence of verapamil. In summary, permeability data showed that the BBB model based on porcine cell line PBMEC/C1-2 was able to reflect the BBB in vivo situation for the transport of antihistaminc drugs and to distinguish between first and second generation antihistamines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22764578

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  5 in total

1.  Establishment of a Human Blood-Brain Barrier Co-culture Model Mimicking the Neurovascular Unit Using Induced Pluri- and Multipotent Stem Cells.

Authors:  Antje Appelt-Menzel; Alevtina Cubukova; Katharina Günther; Frank Edenhofer; Jörg Piontek; Gerd Krause; Tanja Stüber; Heike Walles; Winfried Neuhaus; Marco Metzger
Journal:  Stem Cell Reports       Date:  2017-03-23       Impact factor: 7.765

2.  Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers.

Authors:  Salvatore Febbraro; Tim Shea; Ana Santos Cravo
Journal:  Clin Pharmacol Drug Dev       Date:  2020-03-04

3.  Collision cross sections obtained with ion mobility mass spectrometry as new descriptor to predict blood-brain barrier permeation by drugs.

Authors:  Armin Sebastian Guntner; Bernhard Thalhamer; Christian Klampfl; Wolfgang Buchberger
Journal:  Sci Rep       Date:  2019-12-16       Impact factor: 4.379

4.  Inflammation Modulates RLIP76/RALBP1 Electrophile-Glutathione Conjugate Transporter and Housekeeping Genes in Human Blood-Brain Barrier Endothelial Cells.

Authors:  Barbara Bennani-Baiti; Stefan Toegel; Helmut Viernstein; Ernst Urban; Christian R Noe; Idriss M Bennani-Baiti
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

5.  Transport rankings of non-steroidal antiinflammatory drugs across blood-brain barrier in vitro models.

Authors:  Iveta Novakova; Eva-Anne Subileau; Stefan Toegel; Daniela Gruber; Bodo Lachmann; Ernst Urban; Christophe Chesne; Christian R Noe; Winfried Neuhaus
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.